AlphaRose opened their second convertible note with favorable terms, with internal investors priority, from Oct 1st - Nov 30th 2025.

Designed and intiated studies on two new genetic treatments with our proprietary technology, “SOT Caller” These treatments are estimated to each reach 300-700m in AR once approved.

Our animal tox study we just completed showed no adverse events. This study is a smaller version of the IND enabling study we will be performing next. This gives AlphaRose confidence that Rosiphersen will be safe in human trials.

We filed a provisional patent for our new epigenetic platform, “Sot Caller.” This technology has the potential of changing gene expression throughout the human body. In addition to new therapies we create with it, similliar technologies have produced licensing deals in the xB’s. Our plan is to develop this modality with new treatments, and once reach sufficient data, we will be poised to execute partnerships with biotech and pharma.

AUSTIN, Texas, April 29, 2025 /PRNewswire/ – AlphaRose Therapeutics, an advanced preclinical-stage biotechnology company focused on developing and commercializing therapeutics for neurogenetic developmental diseases, today announces the acquisition of Alpha Anomeric SA, a French company with a novel proprietary oligonucleotide chemistry platform (abcDNA). AlphaRose is currently advancing its lead antisense oligonucleotide product, Rosiphersen, through IND-enabling studies with a goal of initiating clinical studies in early 2026. AlphaRose is also developing a novel gene control technology platform and the Alpha Anomeric chemistry platform has the potential to become an integral part of the AlphaRose platform and development programs. Terms of the transaction were not disclosed.

Alpha Anomeric is a French company founded to develop a novel oligonucleotide chemistry platform (“abcDNA”) invented at the University of Bern (CH) by Professor Christian Leumann and Doctor Damien Evoquez. Alpha Anomeric was founded by Doctor Wolfgang Renner together with lead investor Advent Life Sciences and has validated the potential for the technology to be applied broadly in oligonucleotide therapeutic constructs. The novel chemistry platform is designed to enhance the safety, efficacy and applicability of oligonucleotide therapeutics in a variety of disease settings.

Read more in the press release here: https://www.prnewswire.com/news-releases/alpharose-therapeutics-announces-acquisition-of-alpha-anomeric-sa-a-french-company-with-industry-leading-oligonucleotide-technology-302440678.html#:~:text=AlphaRose%20will%20maintain%20Alpha%20Anomeric,global%20basis%2C%20including%20throughout%20Europe.

All contracts, quotes, and plans assembled for manufacturing, fill and finish, regulatory and clinical partners for lead product, “Rosiphersen.”

We completed due diligence and began launch of our Reg CF Round for 5m. www.startengine.com/alpharose

We completed our genetic graph database and initial algorithms to identify amenable genetic mutations.

We succesfuly in licensed our lead product, “Rosiphersen” into AlphaRose Therpauetics from our partner “The To Cure A Rose Foundation.”

Our Company launch with initial pre-seed capital from the Termeer Family Office.